IL311796A - Anti-galectin-9 antibodies and their therapeutic uses - Google Patents
Anti-galectin-9 antibodies and their therapeutic usesInfo
- Publication number
- IL311796A IL311796A IL311796A IL31179624A IL311796A IL 311796 A IL311796 A IL 311796A IL 311796 A IL311796 A IL 311796A IL 31179624 A IL31179624 A IL 31179624A IL 311796 A IL311796 A IL 311796A
- Authority
- IL
- Israel
- Prior art keywords
- galectin
- seq
- set forth
- complementarity determining
- determining region
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163251227P | 2021-10-01 | 2021-10-01 | |
| US202163277384P | 2021-11-09 | 2021-11-09 | |
| PCT/US2022/077408 WO2023056461A1 (en) | 2021-10-01 | 2022-09-30 | Anti-galectin-9 antibodies and therapeutic uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL311796A true IL311796A (en) | 2024-05-01 |
Family
ID=85783695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL311796A IL311796A (en) | 2021-10-01 | 2022-09-30 | Anti-galectin-9 antibodies and their therapeutic uses |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250269019A1 (https=) |
| EP (1) | EP4392068A4 (https=) |
| JP (1) | JP2024536201A (https=) |
| KR (1) | KR20240082393A (https=) |
| AU (1) | AU2022355201A1 (https=) |
| CA (1) | CA3233331A1 (https=) |
| IL (1) | IL311796A (https=) |
| MX (1) | MX2024004012A (https=) |
| WO (1) | WO2023056461A1 (https=) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7581238B2 (ja) * | 2019-05-01 | 2024-11-12 | ニューヨーク・ユニバーシティ | 抗ガレクチン９抗体およびその使用 |
| US20220332832A1 (en) * | 2019-08-01 | 2022-10-20 | New York University | Combined cancer therapy of anti-galectin-9 antibodies and chemotherapeutics |
-
2022
- 2022-09-30 MX MX2024004012A patent/MX2024004012A/es unknown
- 2022-09-30 CA CA3233331A patent/CA3233331A1/en active Pending
- 2022-09-30 KR KR1020247014491A patent/KR20240082393A/ko active Pending
- 2022-09-30 JP JP2024519470A patent/JP2024536201A/ja active Pending
- 2022-09-30 IL IL311796A patent/IL311796A/en unknown
- 2022-09-30 WO PCT/US2022/077408 patent/WO2023056461A1/en not_active Ceased
- 2022-09-30 EP EP22877637.3A patent/EP4392068A4/en active Pending
- 2022-09-30 AU AU2022355201A patent/AU2022355201A1/en active Pending
- 2022-09-30 US US18/697,500 patent/US20250269019A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3233331A1 (en) | 2023-04-06 |
| JP2024536201A (ja) | 2024-10-04 |
| EP4392068A4 (en) | 2026-03-11 |
| AU2022355201A1 (en) | 2024-04-04 |
| WO2023056461A1 (en) | 2023-04-06 |
| EP4392068A1 (en) | 2024-07-03 |
| KR20240082393A (ko) | 2024-06-10 |
| US20250269019A1 (en) | 2025-08-28 |
| MX2024004012A (es) | 2024-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3394103T3 (fi) | Anti-PD-1-vasta-aineiden ja bispesifisten anti-CD20-/anti-CD3-vasta-aineiden yhdistelmä syövän hoitoon | |
| FI3810281T3 (fi) | Menetelmiä syövän hoitamiseksi bispesifisillä anti-CD3XMUC16-vasta-aineilla ja anti-PD-1-vasta-aineilla | |
| IL261019A (en) | Antibodies to 6 -il and their use | |
| JP2020508317A5 (https=) | ||
| IL295230A (en) | Combination therapy with anti-cd73 antibodies | |
| JP2019515008A5 (https=) | ||
| JP2021528423A5 (https=) | ||
| WO2019186273A4 (en) | Subcutaneous dosing of anti-cd38 antibodies | |
| JP2015534579A5 (https=) | ||
| RU2017107559A (ru) | Лечение раковых заболеваний с применением анти-nkg2a средств | |
| FI3455259T3 (fi) | Anti-PD-1-vasta-aineiden ja sädehoidon yhdistelmä syövän hoitoon | |
| RU2017108173A (ru) | Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1 | |
| JP2023524149A5 (https=) | ||
| JP2018507220A5 (https=) | ||
| JP2014533279A5 (https=) | ||
| JP2022531408A5 (https=) | ||
| JP2010520290A5 (https=) | ||
| JP2022512851A5 (https=) | ||
| JP2020515577A5 (https=) | ||
| JP2024533067A5 (https=) | ||
| JP2019524820A5 (https=) | ||
| JP2023510199A5 (https=) | ||
| JP2022512346A5 (https=) | ||
| JP2024528877A5 (https=) | ||
| JP2025509567A5 (https=) |